Listed by the USPTO as ALDARONDO, DASIA ALI
Tech Center 1600 • Art Units: 1600 1625 1633 1644 1645 1646 1647 1658
This examiner grants 0% of resolved cases
Examiner Dasia Ali Aldarondo is assigned to Tech Center 1600 and Art Unit 1600. The examiner has a total of 4 resolved cases. Currently, the data shows an allowance rate of 0.0 percent, with a median of 1377 days to allowance for the cases handled. This pendency of 1377 days suggests a prosecution cycle for applications in this docket.
The interview lift is recorded at 0.0 percent, indicating that interviews have not yet resulted in a change to the allowance outcomes for this examiner. Major entities that have appeared before this examiner include The Regents of the University of California, University of Florida Research Foundation Inc., and Citibank, N.A. Legal representation has been provided by firms such as Wolf Greenfield & Sacks, P.C., Bozicevic, Field & Francis LLP, and Cantor Colburn LLP. Given the sample of 4 resolved cases, practitioners should monitor how these trends evolve. The 1377 days median pendency remains a figure for setting expectations alongside the 0.0 percent allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18286453 | COMPOSITIONS AND METHODS FOR TREATING OBESITY | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18682785 | READY TO USE COMPOSITIONS OF CETRORELIX ACETATE | Non-Final OA | CITIBANK, N.A. |
| 18579227 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-SYNUCLEINOPATHIES | Non-Final OA | The Johns Hopkins University |
| 18279848 | PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE TARGETING OF TUMORS | Final Rejection | The General Hospital Corporation |
| 18703963 | COMBINATION OF HUMAN NATURAL KILLER CELLS AND MACROPHAGES FOR CANCER THERAPY | Non-Final OA | The Regents of the University of California |
| 18568218 | ANTIBODIES THAT STIMULATE NK CELL-MEDIATED CYTOTOXICITY | Non-Final OA | The Regents of the University of California |
| 18281532 | TRANSPLANTED CELL PROTECTION VIA MODIFIED Fc RECEPTORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18292514 | COMBINATION THERAPY USING EXOSOME SECRETION INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | Research & Business Foundation SUNGKYUNKWAN UNIVERSITY |
| 18685103 | COMBINATION DRUG | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18573732 | CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL | Non-Final OA | MERZ PHARMA GMBH & CO. KGAA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Dasia Ali Aldarondo were allowed (4 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dasia Ali Aldarondo took 1,377 days on average from filing to allowance.
Dasia Ali Aldarondo examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
